Telix Bolsters Board with Pharma and Finance Veterans

Event summary

  • Telix appoints Maria Rivas, MD, and William Jellison as Non-Executive Directors, effective May 11, 2026.
  • Dr. Rivas brings 25+ years in late-stage clinical development and commercialization, including roles at Pfizer.
  • Mr. Jellison has 30+ years in corporate finance and audit committee leadership, formerly CFO at Stryker.
  • Appointments align with Telix's evolution as a dual-listed, global commercial-stage biopharmaceutical company.

The big picture

Telix's board expansion reflects its transition to a commercial-stage biopharmaceutical company with a global footprint. The appointments of Rivas and Jellison underscore a focus on strengthening governance and financial oversight as Telix navigates dual listings and complex regulatory environments. This move aligns with broader industry trends where biopharma firms bolster boards with cross-functional expertise to support scaling operations and product commercialization.

What we're watching

Governance Dynamics
How the new directors' expertise in U.S. public company governance will shape Telix's strategic decisions.
Clinical Leadership
Whether Dr. Rivas' background in oncology and rare diseases will accelerate Telix's product pipeline.
Financial Oversight
The pace at which Mr. Jellison's financial acumen impacts Telix's capital allocation and M&A strategy.